一起由于补碘引起的群发性癔病的调查报告

2004年6月1日至4日,某乡中学发生一起36名学生陆续以头晕、恶心、头痛、腹痛为主要症状到乡卫生院就诊的事件。经流行病学调查、临床资料分析和实验室检测,证实该事件为一起由于补碘所引起的群发性癔病,现将调查结果报告如下。1流行病学调查1.1发病经过:首例就诊学生6月1日15时以恶心、头痛、腹痛为主要症状就诊。以后陆续有类似症状的学生发病,至6月4日凌晨1时30分,共有36名学生就诊。发病高峰在6月3日13时以后。36例学生均为某乡中学初一至初三的学生,其中女生32人,男生4人;年龄在13~17岁,其中13岁3人,14岁16人,15岁7人,16岁9人,17岁1人。…     

hTERT启动子调控hNIS基因介导肺癌细胞碘摄取和131I治疗的实验研究

目的 构建含人端粒酶反转录酶(hTERT)核心启动子调控的人钠/碘同向转运体(hNIS)基因重组腺病毒,并靶向转染至肺癌A549细胞中特异性表达.探讨hTERT启动子调控的hNIS基因介导放射性碘治疗肿瘤的可能性.方法 应用AdEasy系统构建重组腺病毒Ad-hTERT-hNIS,同时构建巨细胞病毒(CMV)启动子调控的hNIS重组腺病毒Ad-CMV.hNIS作为阳性对照,不含hNIS的重组腺病毒Ad-CMV作为阴性对照.应用反转录.聚合酶链反应(RT-PCR)方法验证hTERT在转染肿瘤细胞中的转录活性,摄碘实验检测表达的hNIS蛋白功能,细胞克隆形成实验评价131I对转染肿瘤细胞的毒性作用.结果 成功构建重组腺病毒Ad-hTERT-hNIS、Ad-CMV-hNIS及Ad-CMV,并经PCR验证正确.RT-PCR证实hNIS cDNA能从Ad-hTERT-hNIS转染的细胞中扩增出来.Ad-hTERT-hNIS和Ad-CMV-hNIS转染的肺癌A549细胞摄碘能力比阴性对照组Ad-CMV转染的细胞分别提高了23和31倍,且摄碘能力可以被NaClO4抑制.Ad-hTERT-hNIS和Ad-CMV-hNIS转染的肺癌A549细胞均可被131I杀死,2组细胞成活率分别为(31.2±1.45)%和(23.6±4.08)%,而阴性对照组和未转染病毒组分别为(89.0 ±2.99)%和(91.2 ±4.63)%.结论 hTERT启动子调控的hNIS重组腺病毒转染肿瘤细胞后,应用131I治疗有望成为一种新的基因靶向治疗手段.     

广东省梅县重点人群碘营养状况调查分析

Objective To estimate the present salt iodine content and iodine nutrition need of high risk population of iodine deficiency disorder in Meixian County. Methods Each primary school was selected from urban and rural areas(Xiyang Town, 20 kilometers away from Meixian County), the goiter rate of 8 to 10 year-old students was examined and urinary iodine and household salt iodine was sampled. Twenty to 40 year-old women of childbearing age nearby schools around the urban and villages around Xiyang Town were selected to collect their urine and salt samples. At urban hospitals and rural health centers, 0 to 2 year-old infant urine samples were collected, Thyroid gland was palpated and urinary iodine was determined by iodine in urine by As3+-Ce4+catalytic spectrophotometry, salt iodine was determined by direct titration. Results The goiter rates of 8 to 10 year-old students were 1.5 % (3/200), 1.0% (1/100) for the urban area and 2.0% (2/100) for rural area. Median of urinary iodine in 8 to 10 year-old students, infants, women of childbearing age averaged at 237.1 μg/L and 280.1, 234.7,187.6 μg/L respectively, with each being 287.4,245.0,205.5 μg/L in urban area and 278.9,228.5,176.4 μg/L in rural area. Women of childbearing age had a higher percentage of urinary iodine < 50.0 μg/L than students,students had a higher percentage than infants, each being 7.5%(15/200), 4.5%(9/200), 4.0%(4/100). The ration of urinary iodine > 300.0 μg/L was more in infants than in students, that in students was more than that in women of childbearing age, each being 33.0% (33/100), 30.0% (60/200),22.5% (45/200). The median of salt iodine was 27.2 mg/kg. The coverage of iodized salt was 100.0%(400/400). Ninty-seven percent(194/200) and 96.0% (192/200) of qualified iodized salt were consumed in urban area and in rural area. Conclusions The amount of iodine added to salt meets the requirement in the 3 kinds population risk of iodine deficiency disorder. But a higher iodine status has been found out in students and infants. It is reasonable to decrease the present salt iodine content.     

离子电极法测定SMZ片剂含量的研究

目的：研究用离子电极法测定SMZ片剂含量的效果。方法：用碘离子选择电极作为指示电极，KI溶液回滴过量Ag^ 。结果：测定结果正确，符合药典要求。结论：离子电极法是测定SMZ片剂含量的有效方法。     

碘对比剂在CT检查中的应用

我院自 1994年使用CT检查以来 ,需增强检查者的比例越来越高。增强检查确实提供了CT平扫不可替代的诊断信息 ,但是碘对比剂的副作用却令人担忧 ,因此 ,CT室的护理人员应认真做好对患者的筛选、敏试工作 ,严格掌握禁忌证 ,加强对副反应的预防性措施及意外抢救工作 ,合理使用对比剂 ,现将我院应用碘对比剂的方法介绍如下。1　严格掌握禁忌证严重的甲状腺功能亢进、失代偿性心肌功能不全者禁忌。妊娠及急性盆腔炎症时禁行子宫输卵管造影。2　认真筛选高危因素有碘造影剂过敏、严重肝肾功能损害、心脏和循环功能不全、肺气肿、体质极差者 ,重…     

CT增强碘造影剂致过敏性休克1例

为增加病变组织与正常组织显示密度的差别以明确诊断,在CT检查中常使用造影剂作增强检查。现报道1例因碘造影剂增强所致的过敏性休克。     

乙胺碘呋酮致角膜穿孔的临床分析

目的 探讨乙胺碘呋酮致角膜穿孔的因素。方法 32例48眼随访10年，观察用药剂量及疗程对角膜细胞凋亡的影响。结果 应用乙胺碘呋酮后角膜出现色素沉着，角膜个别细胞凋亡、脱落，形成溃疡，甚至穿孔。上述改变随每日药量和疗程的增加而增加。结论 若每日用药在100mg以内，不出现色素沉着；若每日用药在100—200mg，极少出现色素沉着；若每日用药在400mg以上，6周以内均可出现角膜溃疡、穿孔。如果用药1—2个月停药1周，则可避免角膜并发症的发生，损伤的程度随每日用药量和疗程而增加。     

碘-125放射粒子组织间永久植入治疗普外科恶性肿瘤48例临床观察

普外科恶性肿瘤范围较广，包括甲状腺癌、乳腺癌以及腹部恶性肿瘤，80％以上为腺癌，男性占43％，女性占57％，女性高于男性。普外科恶性肿瘤以外科手术为主，放疗、化疗为辅。但对中晚期的恶性肿瘤切除后预防性植入、残余肿瘤不能切除以及术后复发、转移的肿瘤已失去手术机会的患者，我院开展放射粒子永久植入治疗普外科的恶性肿瘤共48例，其中甲状腺瘤6例，乳腺癌7例，腹壁种植癌2例，腹主动脉上癌2例，胃肠癌17例，胰腺癌6例，     

胺碘酮联合卡托普利治疗阵发性房颤的临床疗效观察

目的:观察胺碘酮联合卡托普利治疗阵发性房颤(AF)的疗效,并探讨其机制与安全性。方法:将186例AF患者随机分为观察组和对照组,观察组给予口服胺碘酮和卡托普利,对照组则单用胺碘酮。结果:经过治疗,观察组的总有效率、随访2年后LVEF高于对照组,差异有显著性(P<0.05)。两组不良反应发生情况类似,患者均可耐受。结论:胺碘酮联合卡托普利治疗AF,疗效显著,作用持久,无严重不良反应发生,可以有效、安全地应用于临床。